Hyperthyroidism (n = 20) | Hypothyroidism (n = 93) | P | t/ x2/Z | |
---|---|---|---|---|
Gender (n, %) | 0.460 | 1.057 | ||
Male | 17(85.0) | 69(74.2) | ||
Female | 3(15.0) | 24(25.8) | ||
Age(years,x ± s) | 56.5 ± 8.1 | 58.9 ± 11.1 | 0.353 | 0.933 |
BMI | 23.7 ± 2.9 | 23.3 ± 3.6 | 0.729 | 0.348 |
Diabetes | 1.000 | 0.000 | ||
Yes | 3(15.0) | 15(16.1) | ||
No | 17(85.0) | 78(83.9) | ||
Evaluation time [weeks,M(Q1,Q3)] | 14.0(9.0, 29.5) | 11.0(3.0, 25.5) | 0.117 | 1.566 |
Hepatocellular carcinoma (n,%) | 0.347 | - | ||
Yes | 20(100.0) | 85(91.4) | ||
No | 0(0.0) | 8(8.6) | ||
Staging of BCLC system(n,%) | 1.000 | 0.000 | ||
B | 4(15.0) | 21(19.4) | ||
C | 16(85.5) | 72(80.6) | ||
HBV or HCV(n,%) | 19(77.4) | 83(85.0) | 0.710 | 0.138 |
Cirrhosis (n,%) | 18(80.5) | 65(87.8) | 0.384 | 0.759 |
Decompensation stage (n,%) | 6(33.3) | 61(65.6) | 0.010 | 6.559 |
Yes | 12(66.7) | 32(34.4) | ||
No | ||||
Previous or combined treatment (n,%) | 7(35.0) | 9(9.7) | 0.003 | 8.684 |
Surgical resection | 16(80.0) | 69(74.2) | 0.585 | 0.298 |
TAE or TACE | 11(55.0) | 44(47.3) | 0.533 | 1.389 |
Tumor ablation | 13(85.0) | 64(68.8) | 0.740 | 0.110 |
Targeted agent | 0(0.0) | 6(6.5) | 0.588 | - |
Systemic chemotherapy | 1(5.0) | 13(14.0) | 0.464 | 0.535 |
Radiotherapy | 0(0.0) | 13(14.0) | 0.120 | - |
Name of PD-1 monoclonal antibody (n,%) | 0.827 | 0.048 | ||
Sintilimab | 10(50.0) | 49(52.7) | ||
Camrelizumab | 10(50.0) | 44(47.3) | ||
Thyroid antibody (n,%) | 1.000 | 0.000 | ||
Positive | 2(22.2) | 5(20.0) | ||
Negative | 7(77.9) | 20(80.0) |